Neuroendocrine Tumors and Survival Rates in Multiple Endocrine Neoplasia Type 1 Patients: Impact of Gender Difference
Neuroendocrinology · 28.10.2024 · 115 (5) · 364-370
DOI: 10.1159/000542143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuroendocrinology, online erschienen am 28.10.2024. Verfasst von Roberta Modica und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Endocrinology, Diabetology and Andrology Unit, Federico II University of Naples, Naples, Italy. Hauptthemen laut MEDLINE: Multiple Endocrine Neoplasia Type 1, Neuroendocrine Tumors, Sex Characteristics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Introduction
Multiple endocrine neoplasia type 1 (MEN-1) is the most common inherited syndrome associated with NET development and gender-specific differences are emerging in neuroendocrine tumors (NETs). This study aimed to analyze gender difference in a single cohort of MEN-1 patients focusing on duodeno-pancreatic (DP)-NET and survival rates.
Methods
MEN-1 patients referred to the Endocrinology Unit of the “Federico II” University of Naples, ENETS CoE, were retrospectively evaluated.
Results
Among 100 MEN-1 patients enrolled, 59 (59%) were female and 41 (41%) male, and mean age at diagnosis was 39.4 years (range 5–86). No statistically significant association was identified between MEN-1 clinical manifestations and gender (primary hyperparathyroidism [PHPT] p: 1.0, DP-NET p: 0.83, pituitary adenoma [PA] p: 0.84, lung NET p: 0.64, and thymic NET p: 0.10), and similarly, age at diagnosis of MEN-1 and its individual manifestations was similar between genders. Survival analysis revealed no statistically significant difference between genders in DP-NET patients regarding progression disease p: 1.0 and death p: 1.0. Mean progression-free survival (PFS) of patients with DP-NET was 98.6 months (range 3–288), and mean overall survival (OS) was 130.1 months (range 3–444 months), without differences between genders (PFS p: 0.67 and OS p: 0.60). The Kaplan-Meier survival curves for PFS and OS showed no differences between genders (PFS p: 0.92; OS p: 0.87).
Conclusion
In this MEN-1 cohort, no gender differences in the occurrence of PHPT, PA, DP-NET, lung NET, and thymic NET, nor in survival outcomes including PFS and OS within the DP-NET subcohort, emerged. Therefore, this study supports similar screening and follow-up for both male and female MEN-1 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Medicine and Surgery, Endocrinology, Diabetology and Andrology Unit, Federico II University of Naples, Naples, Italy.
- Department of Clinical Medicine and Surgery, Endocrinology, Diabetology and Andrology Unit, Federico II University of Naples, Naples, Italy, colao@unina.it.
- UNESCO Chair "Education for Health and Sustainable Development", Federico II University, Naples, Italy, colao@unina.it.
Zitieren
APA
Modica, R., Liccardi, A., Minotta, R., Benevento, E., Cannavale, G., Di Iasi, G., & Colao, A. (2024). Neuroendocrine Tumors and Survival Rates in Multiple Endocrine Neoplasia Type 1 Patients: Impact of Gender Difference. Neuroendocrinology, 115(5), 364-370. https://doi.org/10.1159/000542143
Vancouver
Modica R, Liccardi A, Minotta R, Benevento E, Cannavale G, Di Iasi G, et al. Neuroendocrine Tumors and Survival Rates in Multiple Endocrine Neoplasia Type 1 Patients: Impact of Gender Difference. Neuroendocrinology. 2024;115(5):364-370. doi:10.1159/000542143
BibTeX
@article{Modica2024,
author = {Modica, Roberta and Liccardi, Alessia and Minotta, Roberto and Benevento, Elio and Cannavale, Giuseppe and Di Iasi, Gianfranco and Colao, Annamaria},
title = {Neuroendocrine Tumors and Survival Rates in Multiple Endocrine Neoplasia Type 1 Patients: Impact of Gender Difference},
journal = {Neuroendocrinology},
year = {2024},
volume = {115},
number = {5},
pages = {364--370},
doi = {10.1159/000542143}
}
EUVIMED